Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.
Isabel ConceiçãoJohn L BerkMarkus WeilerPedro A KowacsNoel R DasguptaSami KhellaChi-Chao ChaoShahram AttarianT Jesse KwohShiangtung W JungJersey ChenNicholas J VineyRosie Z YuMorie GertzAhmad MasriMárcia Waddington CruzTeresa CoelhoPublished in: Journal of neurology (2024)
Switching from inotersen to eplontersen further reduced serum TTR, halted disease progression, stabilized QoL, restored platelet count, and improved tolerability, without deterioration in nutritional status. This supports a positive benefit-risk profile for patients with ATTRv-PN who switch from inotersen to eplontersen.